Research
Hormonal
Older anti-obesity medications (Orlistat, Naltrexone/Bupropion, Phentermine/Topiramate, Liraglutide) have limited efficacy compared to newer GLP-1/GIP agonists.
Older obesity medications provide moderate weight loss (8-10%). They are established options but are less effective than the newest injectable treatments.
GoodQualifiesHIGH confidence
However, until now, the mentioned obesity treatment drugs had limitations... average 8-10% weight loss effect...
Why this rating
Based on clinical trials cited.
Source
Current State of Pharmacotherapy in Obesity
Won Jun Kim · Korean Journal of Gastroenterology · 2024
DOI 10.4166/kjg.2024.016
narrative_reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Long-term pharmacotherapy for obesity requires medications with proven efficacy and safety, as lifestyle modification alone is often insufficient for sustained weight loss.Good
- GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual GIP/GLP-1 agonists (Tirzepatide) offer superior weight loss compared to older anti-obesity medications.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →